By Hendra Lukman 
A groundbreaking antibody therapy developed at Stanford Medicine is poised to transform the landscape of stem cell transplantation, offering a less toxic alternative to conventional chemotherapy and radiation for patients with Fanconi anemia. Early results from a phase 1 clinical trial indicate that this innovative approach can effectively prepare patients for life-saving transplants, dramatically reducing the severe side effects associated with traditional conditioning regimens. This breakthrough holds immense promise not only for individuals with Fanconi anemia but potentially for a wider range of inherited blood disorders requiring stem cell transplantation.
A New Era for Fanconi Anemia Treatment
Fanconi anemia is a rare, inherited condition characterized by a defect in DNA repair mechanisms, leading to progressive bone marrow failure. This deficiency compromises the body’s ability to produce essential blood cells, including red blood cells, white blood cells, and platelets. As a result, individuals with Fanconi anemia are highly susceptible to debilitating fatigue, chronic infections, and life-threatening bleeding. Without intervention, the condition typically progresses to fatal bone marrow failure by the time patients reach their early teens, with approximately 80% experiencing this by age 12.
Historically, the most effective treatment for Fanconi anemia has been a stem cell transplant, where a patient’s diseased bone marrow is replaced by healthy stem cells from a donor. However, preparing patients for this procedure has traditionally involved high-dose chemotherapy and/or radiation. These potent treatments, while crucial for eliminating the patient’s existing faulty stem cells, carry significant risks, including severe toxicity, secondary cancers, and long-term organ damage. It is estimated that nearly all Fanconi anemia patients treated with conventional methods develop secondary cancers by age 40, highlighting the urgent need for safer alternatives.
The Stanford Medicine study, published in the prestigious journal Nature Medicine, represents a paradigm shift by demonstrating the efficacy of an antibody-based conditioning regimen. This novel approach targets a specific protein, CD117, found on the surface of blood-forming stem cells. By utilizing an antibody that binds to CD117, researchers were able to selectively eliminate the patient’s own unhealthy stem cells without resorting to the damaging effects of radiation or genotoxic chemotherapy agents like busulfan.
The Briquilimab Breakthrough: Eliminating Toxicity
The core of this revolutionary treatment lies in the use of an antibody known as briquilimab. This targeted therapy acts as a precise instrument, identifying and neutralizing the patient’s own hematopoietic stem cells. Unlike the indiscriminate and destructive nature of radiation and chemotherapy, briquilimab offers a more refined approach, minimizing collateral damage to healthy tissues and organs.
Dr. Agnieszka Czechowicz, MD, PhD, an assistant professor of pediatrics and co-senior author of the study, emphasized the profound impact of this development. "We were able to treat these really fragile patients with a new, innovative regimen that allowed us to reduce the toxicity of the stem cell transplant protocol," she stated. "Specifically, we could eliminate the use of radiation and genotoxic chemotherapy called busulfan, with exceptional outcomes." This elimination of harsh treatments is a critical step towards making stem cell transplantation a more accessible and less daunting option for a wider patient population.
The phase 1 clinical trial involved three young children diagnosed with Fanconi anemia. These children, all under the age of 10 and presenting with distinct genetic variants of the disorder, underwent the novel treatment. Each patient received a single intravenous dose of briquilimab approximately 12 days prior to their stem cell transplant. Following this, they were administered standard immune-suppressing medications but were spared the traditional busulfan and radiation.
The results were nothing short of remarkable. Within two weeks of the transplant, the donated stem cells had successfully engrafted in the patients’ bone marrow. Crucially, none of the children experienced graft rejection, a common complication in transplantation. By the one-month mark post-transplant, donor cells had already replaced nearly all of the patients’ original stem cells. The research team had initially set a modest goal of achieving just 1% donor cell presence, but to their elation, all three children demonstrated nearly 100% donor cell chimerism two years later.
"We’ve been surprised by how well it’s worked," Dr. Czechowicz remarked. "We were optimistic that we would get here, but you never know when you’re trying a new regimen." This sentiment underscores the cautious optimism and scientific rigor that underpins such groundbreaking research.
Addressing the Donor Match Challenge
Beyond revolutionizing the conditioning regimen, the Stanford team also addressed another significant hurdle in the realm of stem cell transplantation: the persistent challenge of finding fully matched donors. Historically, a substantial percentage of patients, estimated to be up to 40%, have been unable to receive transplants due to the scarcity of compatible donors.
To overcome this critical barrier, researchers implemented a modified approach to donor bone marrow preparation. This involved enriching the donated marrow for CD34+ cells, which are the primitive blood-forming stem cells, while simultaneously removing immune cells known as alpha/beta T-cells. The removal of these T-cells is vital, as they are a primary cause of graft-versus-host disease (GVHD), a dangerous complication where the donor’s immune system attacks the recipient’s body.
This innovative technique, pioneered by Dr. Alice Bertaina, MD, PhD, a key collaborator in the study, enables safe transplantation even from half-matched donors, including parents. This significantly broadens the pool of potential donors, thereby increasing the chances of a successful transplant for a greater number of patients.
Dr. Rajni Agarwal, MD, professor of pediatric stem cell transplantation and co-first author, highlighted the profound implications of this donor flexibility. "We are expanding the donors for stem cell transplantation in a major way, so every patient who needs a transplant can get one," she stated. This expansion of donor options is a critical step towards achieving the goal of making stem cell transplantation universally accessible.
A Child’s Triumph: Ryder’s Journey
The human impact of this research is vividly illustrated by the story of Ryder Baker, an 11-year-old from Seguin, Texas. Ryder was the first child to receive the novel antibody therapy at Lucile Packard Children’s Hospital Stanford in early 2022. Prior to the transplant, Ryder’s Fanconi anemia significantly impacted his quality of life, leaving him perpetually fatigued and unable to fully participate in childhood activities.
His mother, Andrea Reiley, recounted the stark transformation. "He was so tired, he didn’t have stamina. It’s completely different now," she said, describing how her son’s condition no longer hinders him. Today, Ryder is a picture of health and vitality. He has regained his energy, successfully completed fifth grade, actively participates in sports, and even received an "Up and Coming Player" award from his school soccer team.
Ryder’s recovery, while a testament to his resilience, also highlights the demanding nature of transplantation, even with a less toxic regimen. He spent over a month in the hospital and experienced temporary exhaustion, nausea, and hair loss. "It was heartbreaking to see him go through things like that — I’d rather go through it than my child," Reiley shared, expressing the profound emotional toll on parents. However, the long-term benefits have far outweighed these temporary challenges. Ryder has grown taller, gained weight, and is no longer plagued by the frequent illnesses that once defined his life.
Reiley also instills in Ryder a sense of purpose, emphasizing that his experience as one of the pioneering patients will pave the way for others. "I think he takes a lot of pride in that, too," she noted. This sentiment underscores the altruistic spirit that drives such medical advancements.
Broader Implications and Future Directions
The success of this antibody-based conditioning regimen extends far beyond the initial cohort of Fanconi anemia patients. Researchers believe this approach has the potential to revolutionize stem cell transplantation for a multitude of inherited diseases that currently necessitate this life-saving procedure.
"Bone marrow or stem cell transplants are most commonly used in blood cancers, in which the bone marrow is full of malignant cells and patients have no other options," explained Dr. Czechowicz. "But as we’re making these transplants better and safer, we can expand them to more patients including those with many different diseases."
The implications for elderly cancer patients, who often cannot tolerate the rigors of traditional conditioning regimens, are particularly significant. "That population is often at a disadvantage," commented Dr. Agarwal. "It may provide us with a way to treat them with less intensity so it’s possible for them to get a transplant."
Stanford’s research team is actively pursuing these avenues. They are currently leading a phase 2 clinical trial to further evaluate the antibody approach in a larger group of children with Fanconi anemia. Additionally, they are exploring its applicability to other rare bone marrow failure disorders, such as Diamond-Blackfan anemia.
The development of next-generation antibody-based treatments is also underway, aiming to further refine outcomes and enhance the safety profile of these procedures. This ongoing commitment to innovation reflects Stanford’s long-standing dedication to advancing stem cell biology and regenerative medicine, a journey that began with foundational research by Dr. Irving Weissman, MD, who initiated studies on blood-forming stem cells in 2004.
A Collaborative Endeavor
This groundbreaking research is the culmination of extensive collaboration among leading institutions and researchers. Beyond Dr. Czechowicz, Dr. Agarwal, and Dr. Bertaina, the study’s co-senior author, Dr. Matthew Porteus, MD, PhD, played a pivotal role. Contributions also came from scientists at the University of California, San Francisco; Kaiser Permanente Bernard J. Tyson School of Medicine; St. Jude Children’s Research Hospital; Memorial Sloan Kettering Cancer Center; and Jasper Therapeutics Inc.
The research was generously supported by anonymous donors, the California Institute of Regenerative Medicine, and the Fanconi Cancer Foundation. Jasper Therapeutics provided the essential antibody, briquilimab, and the Stanford Clinical Trial Program was instrumental in facilitating the study’s implementation.
The journey from initial concept to clinical success has been a lengthy one, spanning over two decades of dedicated research. This triumph in the fight against Fanconi anemia and the promise it holds for other debilitating diseases underscore the power of persistent scientific inquiry and collaborative spirit in transforming patient care and offering hope where it was once scarce. The era of less toxic, more accessible stem cell transplantation has truly begun.